Amplia announces second confirmed complete response in ACCENT trial

June 19, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer. …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

Sussan Ley's sometimes contentious but unquestionably consequential health legacy
February 15, 2026 - Latest News
PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations
February 15, 2026 - Latest News
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - Latest News
'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'
February 16, 2026 - Latest News
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - Australian Biotech

Amplia announces second confirmed complete response in ACCENT trial

This is a preview of subscriber content

Latest Video

Most Read

Sussan Ley's sometimes contentious but unquestionably consequential health legacy

PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'

New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial

New Stories

Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

Director pay rises across ASX healthcare sector, but gender balance remains uneven

Life sciences sector unites to advance women’s leadership at landmark 2026 events

New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial

Medibank funding expansion signals momentum for Emyria’s mental health model

IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending

Sign In

Amplia announces second confirmed complete response in ACCENT trial

This is a preview of subscriber content

Latest Video

Most Read

Sussan Ley's sometimes contentious but unquestionably consequential health legacy

PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'

New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial

Follow Us

New Stories

Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

Director pay rises across ASX healthcare sector, but gender balance remains uneven

Life sciences sector unites to advance women’s leadership at landmark 2026 events

New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial

Medibank funding expansion signals momentum for Emyria’s mental health model

IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending